Table 3. Results of univariate and multivariate Cox regression analysis for PFS (univariate analysis of the significant variables).
| Variables | Progression | ||||||
|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | ||||||
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Types of pathology | 1.953 | 1.180–3.231 | 0.009* | 2.103 | 1.237–3.576 | 0.006* | |
| ECOG PS | |||||||
| 2 | 1 | 1 | |||||
| 1 | 0.096 | 0.024–0.388 | 0.001* | 0.099 | 0.024–0.411 | 0.001* | |
| 0 | 0.177 | 0.052–0.601 | 0.006* | 0.221 | 0.062–0.794 | 0.021* | |
| CEA6W | 1.758 | 1.066–2.900 | 0.027* | 1.810 | 1.091–3.003 | 0.022* | |
| PLT12W | 1.754 | 1.044–2.918 | 0.034* | 1.607 | 0.995–2.703 | 0.074 | |
*, P<0.05. PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; PLT, platelet; HR, hazard ratio; CI, confidence interval.